Results 51 to 60 of about 13,664 (205)
Mediterranean Journal of Hematology and Infectious Diseases, 2014 Diffuse alveolar hemorrhage is a serious complication post stem cell transplantation with no proven definitive treatment, resulting in high mortality. Recombinant factor VIIa has been occassionaly used in such patients with good results. We report here a
Dharma Choudhary +3 more
doaj
A Comparison between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients with Congenital Factor VII Deficiency [PDF]
, 2015 In order to establish the efficacy and biosimilar nature of AryoSeven to NovoSeven in the treatment of congenital factor VII (FVII) deficiency, patients received either agent at 30 1/4g/kg, intravenously per week for 4 weeks, in a randomized fashion. The
Abolghasemi, H. +16 more
core
Spontaneous bleeding in a patient with malignant lymphoma: A case of acquired hemophilia [PDF]
, 2000 Background: Acquired hemophilia is a rare condition which can be associated with lymphoproliferative disease. Case Report: Eleven yea rs after the diagnosis of immunocytoma had been made, a 72-year-old man developed a high-titer factor VIII inhibitor. At
Brack, N. +5 more
core +1 more source
Transfusion Medicine, EarlyView.Abstract Solid organ transplant is associated with high rates of anaemia and transfusion, but there is little comparative data on interventions such as erythropoietin‐stimulating agents (ESAs) and intravenous (IV) iron. We conducted a systematic review examining the association of ESAs and IV iron with outcomes in adults undergoing solid organ ...
Frank Lee +13 more
wiley +1 more source
Asian Journal of Transfusion Science, 2012 Background: Factor VIIa (recombinant) has an off-label use to control life-threatening bleeding that is refractory to other measures and was shown to decrease transfusion requirements.
Said D Abuhasna +2 more
doaj +1 more source
Combined Factor VII and X Deficiency [PDF]
, 2011 Factor VII deficiency and factor X deficiency and very rare disorders individually. Combined Factor VII and X is a rare congenital blood disorder with very few cases reported in the literature.
Arora, Sunita +2 more
core
Successful treatment of refractory gastrointestinal bleeding by systemic (oral) ankaferd blood stopper in a patient with Glanzmann thrombasthenia [PDF]
, 2015 Background: Glanzmann Thrombasthenia (GT) is a genetic platelet dysfunction and a life threatening disease. Ankaferd Blood Stopper (ABS) is a topical hemostatic agent of herbal origin which has been recently made available for clinical use.
Doğu, Mehmet Hilmi +3 more
core +2 more sources
Co‐localization of tau and TDP‐43 after extracellular vesicle delivery to cells
The FEBS Journal, Volume 293, Issue 5, Page 1495-1515, March 2026.Extracellular vesicles (EVs) derived from donor cells transfected with EGFP–2N4R‐tau or mCherry‐wtTDP‐43 were taken up by recipient cells, leading to cytosolic co‐localization of tau and TDP‐43. Molecular modeling revealed that tau and TDP‐43 directly interact through hydrogen bonding, suggesting a mechanistic link underlying their co‐pathology ...
Farhang Aliakbari +6 more
wiley +1 more source
A surveillance system to assess the need for updating systematic reviews. [PDF]
, 2013 BackgroundSystematic reviews (SRs) can become outdated as new evidence emerges over time. Organizations that produce SRs need a surveillance method to determine when reviews are likely to require updating.
Ahmadzai, Nadera +11 more
core +1 more source
ChemMedChem, Volume 21, Issue 4, 25 February 2026.Polypharmacology is expected to produce higher therapeutic efficacy and lower cytotoxic and side effects. Compound 15 exhibited strong inhibition of the human carbonic anhydrase isoforms IX and XII and selectivity toward the adverse isoforms I and II.
Michela Puxeddu +21 more
wiley +1 more source